连续流左心室辅助装置桥接心脏移植与严重原发性移植物功能障碍风险
该研究回顾性分析2009至2017年480例成人心脏移植患者,严重原发性移植物功能障碍(PGD)定义为移植后24小时内需机械循环支持。CF-LVAD桥接患者中,辅助支持>1年、移植前肌酐升高、CVP/PCWP比值升高及移植前使用胺碘酮与严重PGD相关,且严重PGD患者1年生存率降低(78.3% vs 91.8%,p=0.007)。
要点
- CF-LVAD桥接心脏移植与严重PGD风险增加独立相关(OR 3.86)。
- 辅助支持>1年、移植前肌酐升高、CVP/PCWP比值升高及胺碘酮使用可识别高危患者。
- 严重PGD患者移植后1年生存率显著降低(78.3% vs 91.8%)。
核心结论
- 使用CF-LVAD桥接心脏移植与严重PGD风险增加相关。
- 辅助支持时间延长、肾功能不全、右心室功能障碍(以CVP/PCWP比值评估)及移植前胺碘酮使用可能识别高危患者。
研究设计与样本
- 回顾性研究,纳入2009至2017年单中心480例成人心脏移植患者。
- 严重PGD定义为心脏移植后24小时内需机械循环支持。
- 采用多因素logistic回归分析识别严重PGD危险因素,重点关注CF-LVAD桥接移植患者。
主要发现
- 严重PGD患者中80%为CF-LVAD桥接移植者(OR 3.86,95%CI 1.94-7.68,p<0.001)。
- CF-LVAD桥接患者中,辅助支持>1年(OR 2.48,95%CI 1.14-5.40,p=0.022)、移植前肌酐(OR 3.35,95%CI 1.42-7.92,p=0.006)、CVP/PCWP比值升高(OR 3.32,95%CI 1.04-10.60,p=0.043)、移植前胺碘酮使用(OR 2.69,95%CI 1.20-6.20,p=0.022)与严重PGD相关。
- RADIAL评分在该队列中未能准确预测严重PGD。
- 严重PGD患者移植后1年生存率降低(78.3% vs 91.8%,p=0.007)。
临床怎么用
- 对CF-LVAD桥接心脏移植患者应评估严重PGD风险,关注辅助支持时间、肾功能、CVP/PCWP比值及胺碘酮使用。
- RADIAL评分在本队列中预测准确性不足,需谨慎用于风险分层。
局限性
- 单中心回顾性研究,样本量有限,结果外推需谨慎。
- 严重PGD定义基于移植后24小时内机械循环支持需求,可能受临床实践差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary graft dysfunction (PGD) remains a significant cause of post-transplant morbidity and mortality. The exact mechanism and risk factors for this phenomenon remain unknown in the contemporary era. METHODS: In this study we reviewed adult patients undergoing heart transplantation (HT) at our institution between 2009 and 2017. Severe PGD was defined as the need for mechanical circulatory support (MCS) within the first 24 hours after HT. Multivariate logistic regression analysis was used to identify risk factors for severe PGD, focusing on those bridged to transplant (BTT) with a continuous-flow left ventricular assist device (CF-LVAD). RESULTS: Fifty-six of 480 (11.7%) HT patients experienced severe PGD. Eighty percent of the severe PGD patients were BTT with a CF-LVAD (odds ratio [OR] 3.86, 95% confidence interval [CI] 1.94 to 7.68, p < 0.001). Among the BTT patients, significant associations between >1 year of CF-LVAD support (OR 2.48, 95% CI 1.14 to 5.40, p = 0.022), pre-HT creatinine (OR 3.35, 95% CI 1.42 to 7.92, p = 0.006), elevated central venous pressure/pulmonary capillary wedge pressure (CVP/PCWP) ratio (OR 3.32, 95% CI 1.04 to 10.60, p = 0.043), use of amiodarone before HT (OR 2.69, 95% CI 1.20 to 6.20, p = 0.022), and severe PGD were identified. RADIAL score did not accurately predict severe PGD in this contemporary cohort. Those patients who developed severe PGD had decreased 1-year post-transplant survival (78.3% vs 91.8%, p = 0.007). CONCLUSIONS: Use of CF-LVAD as BTT is associated with an increased risk of severe PGD. Increased time on device support, renal dysfunction, right ventricular dysfunction as assessed by CVP/PCWP ratio, and pre-transplant amiodarone may identify those patients at high risk. Further research is warranted focusing on optimal timing of device implantation and transplantation, as well as the underlying mechanisms of PGD.
引用
- Truby LK, Takeda K, Topkara VK, et al. Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2018. PMID: 30206023. doi:10.1016/j.healun.2018.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。